These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28072904)

  • 21. Questions about the 10 x '20 Initiative.
    Outterson K; Powers JH; Gould IM; Kesselheim AS
    Clin Infect Dis; 2010 Sep; 51(6):751-2; author reply 754-5. PubMed ID: 20731566
    [No Abstract]   [Full Text] [Related]  

  • 22. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.
    Infectious Diseases Society of America
    Clin Infect Dis; 2010 Apr; 50(8):1081-3. PubMed ID: 20214473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):491-5. PubMed ID: 16583990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, poland--part I.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):485-90. PubMed ID: 16583989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Letter in response to the Infectious Diseases Society of America's 10 x '20 Initiative.
    Burgess DS; Slain D; Mohr J; Wong-Beringer A; Destache C; Suda K
    Clin Infect Dis; 2010 Sep; 51(6):753; author reply 754-5. PubMed ID: 20731568
    [No Abstract]   [Full Text] [Related]  

  • 27. Time for a change: addressing R&D and commercialization challenges for antibacterials.
    Payne DJ; Miller LF; Findlay D; Anderson J; Marks L
    Philos Trans R Soc Lond B Biol Sci; 2015 Jun; 370(1670):20140086. PubMed ID: 25918443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial stewardship: bridging the gap between quality care and cost.
    Goff DA
    Curr Opin Infect Dis; 2011 Feb; 24 Suppl 1():S11-20. PubMed ID: 21200180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The antibiotic pipeline: reviving research and development and speeding drugs to market.
    Luepke KH; Mohr JF
    Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antibiotics and health care economics].
    Modai J; Droulers AM
    Soins; 1981 Mar; 26(6):38-9. PubMed ID: 6910261
    [No Abstract]   [Full Text] [Related]  

  • 31. Alternative natural sources for a new generation of antibacterial agents.
    Taylor PW
    Int J Antimicrob Agents; 2013 Sep; 42(3):195-201. PubMed ID: 23796893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Elderly patients suffer more from side effects and resistant microorganisms].
    Dahl Knudsen J; Frimodt-Møller N
    Ugeskr Laeger; 2013 Nov; 175(47):2854-7. PubMed ID: 24629384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Phamacoeconomic analysis of antibiotics use in the Clinical Center of Vojvodina].
    Stefan-Mikić S; Jovanović J; Jovanović N; Aleksić-Dordević M; Cvjetković D; Krajcir I
    Med Pregl; 2008; 61 Suppl 1():50-8. PubMed ID: 19248640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Monitoring of antibiotic treatment of patient with a severe bacterial infection].
    Aubert G; Carricajo A
    Ann Fr Anesth Reanim; 2004 Jul; 23(7):704-13. PubMed ID: 15324959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic consequences of antimicrobial resistance.
    Paladino JA; Sunderlin JL; Price CS; Schentag JJ
    Surg Infect (Larchmt); 2002; 3(3):259-67. PubMed ID: 12542927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.
    Towse A; Hoyle CK; Goodall J; Hirsch M; Mestre-Ferrandiz J; Rex JH
    Health Policy; 2017 Oct; 121(10):1025-1030. PubMed ID: 28888660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostics as essential tools for containing antibacterial resistance.
    Okeke IN; Peeling RW; Goossens H; Auckenthaler R; Olmsted SS; de Lavison JF; Zimmer BL; Perkins MD; Nordqvist K
    Drug Resist Updat; 2011 Apr; 14(2):95-106. PubMed ID: 21398170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monopoly pricing of an antibiotic subject to bacterial resistance.
    Herrmann M
    J Health Econ; 2010 Jan; 29(1):137-50. PubMed ID: 20015559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antibiotic pharmacoeconomics].
    Jahnz-Rózyk K
    Pol Merkur Lekarski; 2008 Nov; 25(149):437-8. PubMed ID: 19177784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibiotic resistance as a major public health concern: epidemiology and economic impact.
    Ciorba V; Odone A; Veronesi L; Pasquarella C; Signorelli C
    Ann Ig; 2015; 27(3):562-79. PubMed ID: 26152543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.